Autopsy report · NCT01551628

A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma

“slow patient recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 1 month before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Bio-Cancer Treatment International Limited

Sponsor type

Industry

Conditions

Leukemia; Lymphoma

Interventions

Recombinant human arginase 1 Peg5000

Participants

1

Sites

1

Countries

China

Trials that died the same way

• Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis
  “too slow patient recruitment” (97% match in meaning)
• Evaluation of the Parietex TM Parastomal No Hole Mesh for Repair of Parastomal Hernias in End-colostomies
  “too slow patiënts recruitment” (95% match in meaning)
• Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma
  “slow recruitment of patients” (95% match in meaning)
• Growth Hormone in Poor Responders to IVF Trial
  “Insufficient/slow patient recruitment” (94% match in meaning)
• Tibial Delayed Healing Pivotal Clinical Trial
  “Difficulty in patient recruitment” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.